Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Aptinyx
- 26 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 Aug 2022 According to an Aptinyx media release, detailed data from the study continue to be evaluated.
- 12 Aug 2022 Results published in the Aptinyx Media Release.